CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 525 enrolled
Drug / intervention
Transdermal nicotine patchdrug
Likely dose
Transdermal nicotine patch 21mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01047527
NCT01047527Phase 4Completed

An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence

University of Pennsylvania·interventional·Posted Jan 13, 2010·Updated Jul 8, 2015

In Brief

A Phase 4 clinical trial evaluating Transdermal nicotine patch for Nicotine Dependence. Completed, enrolled 525 participants across 2 sites.

Detailed Summary

The transdermal nicotine patch is the most widely used form of tobacco dependence treatment in the US and Europe, but most smokers are unable to successfully quit with this form of treatment. Failure to respond to this treatment may, to a large extent, be due to the use of nicotine patches for only 8 weeks, the recommended treatment duration. We have found in a controlled randomized clinical trial that using the nicotine patch for 24 weeks can increase quit rates significantly. We propose here a clinical trial to replicate and extend these results to a community setting in the real-world, using the same research design utilized in clinical trials to demonstrate the effectiveness of methadone maintenance therapy for opiate dependence. Specifically, 540 smokers will receive counseling and standard (8-weeks), extended (24-weeks), or maintenance (52 weeks) therapy with transdermal nicotine patches. The main outcome is biochemically-verified smoking cessation at week 52. The cost-effectiveness, safety, and mechanism of effect (e.g., promotion of recovery following a lapse) for maintenance therapy with transdermal nicotine will also be assessed. The study results may change how we treat nicotine dependence with transdermal nicotine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 13, 2010
Enrollment StartJun 1, 2009
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.5 years ago

Interventions

Transdermal nicotine patchdrug

Transdermal nicotine, 21mg/day